| dbo:abstract |
Tralokinumab ist ein monoklonaler Antikörper, der zur Behandlung der atopischen Dermatitis (AD) angewendet wird. Im Juni 2021 wurde er unter dem Namen Adtralza (LEO Pharma) für die Länder der europäischen Union als Arzneimittel zugelassen. In Studien zur Behandlung von schwerem Asthma zeigte sich der Antikörper nicht ausreichend wirksam. (de) Tralokinumab sold under the brand names Adtralza (EU/UK) and Adbry (US) among others, is a human monoclonal antibody used for the treatment of atopic dermatitis. Tralokinumab targets the cytokine interleukin 13. The most common side effects include upper respiratory tract infections (colds and other infections of the nose and throat), reactions at the injection site, and redness and discomfort in the eye. Tralokinumab was approved for medical use in the European Union and in the United Kingdom in June 2021. It was approved for medical use in the United States in December 2021. (en) Тралокинумаб — лекарственный препарат, моноклональное антитело для лечения атопического дерматита. Одобрен для применения: EU, США (2021). (ru) |
| dbo:alternativeName |
Adtralza, Adbry (en) |
| dbo:casNumber |
1044515-88-9 |
| dbo:drugbank |
DB12169 |
| dbo:fdaUniiCode |
GK1LYB375A |
| dbo:kegg |
D09979 |
| dbo:thumbnail |
wiki-commons:Special:FilePath/Tralokinumab_5L6Y.png?width=300 |
| dbo:wikiPageExternalLink |
https://druginfo.nlm.nih.gov/drugportal/name/tralokinumab |
| dbo:wikiPageID |
33024164 (xsd:integer) |
| dbo:wikiPageLength |
16593 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1120064501 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbr:Cambridge_Antibody_Technology dbr:Ulcerative_colitis dbr:Indication_(medicine) dbr:Interleukin_13 dbr:International_nonproprietary_name dbr:MedImmune dbr:Leo_Pharma dbr:Subcutaneous_injection dbr:Protein_Data_Bank dbr:Fragment_antigen-binding dbr:Ribosome_display dbc:AstraZeneca_brands dbr:Atopic_dermatitis dbc:Monoclonal_antibodies dbr:United_States_Adopted_Name dbr:Human_monoclonal_antibody |
| dbp:atcPrefix |
D11 (en) |
| dbp:atcSuffix |
AH07 (en) |
| dbp:c |
6374 (xsd:integer) |
| dbp:caption |
Tralokinumab Fab fragment bound to IL-13. From PDB . (en) |
| dbp:casNumber |
1044515 (xsd:integer) |
| dbp:chemspiderid |
none (en) |
| dbp:dailymedid |
Tralokinumab (en) |
| dbp:drugbank |
DB12169 (en) |
| dbp:h |
9822 (xsd:integer) |
| dbp:kegg |
D09979 (en) |
| dbp:legalCa |
Rx-only (en) |
| dbp:legalEu |
Rx-only (en) |
| dbp:legalStatus |
Rx-only (en) |
| dbp:legalUk |
POM (en) |
| dbp:legalUs |
Rx-only (en) |
| dbp:mabType |
mab (en) |
| dbp:n |
1698 (xsd:integer) |
| dbp:o |
2014 (xsd:integer) |
| dbp:routesOfAdministration |
dbr:Subcutaneous_injection |
| dbp:s |
44 (xsd:integer) |
| dbp:source |
u (en) |
| dbp:synonyms |
CAT-354, tralokinumab-ldrm (en) |
| dbp:target |
dbr:Interleukin_13 |
| dbp:tradename |
Adtralza, Adbry (en) |
| dbp:type |
mab (en) |
| dbp:unii |
GK1LYB375A (en) |
| dbp:verifiedfields |
changed (en) |
| dbp:verifiedrevid |
470612083 (xsd:integer) |
| dbp:watchedfields |
changed (en) |
| dbp:wikiPageUsesTemplate |
dbt:Other_dermatological_preparations dbt:Antineoplastic-drug-stub dbt:Cite_web dbt:Dermatologic-drug-stub dbt:Infobox_drug dbt:Portal_bar dbt:Reflist dbt:Use_dmy_dates dbt:Cascite dbt:Chemspidercite dbt:Drugbankcite dbt:Fdacite dbt:PDB2 dbt:Interleukin_receptor_modulators dbt:Monoclonals_for_immune_system dbt:Monoclonal-antibody-stub |
| dcterms:subject |
dbc:AstraZeneca_brands dbc:Monoclonal_antibodies |
| gold:hypernym |
dbr:Antibody |
| rdf:type |
owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:MonoclonalAntibody yago:WikicatMonoclonalAntibodies yago:Abstraction100002137 yago:Antibody115027189 yago:Chemical114806838 yago:Compound114818238 yago:Macromolecule114944888 yago:Material114580897 yago:Matter100020827 yago:Molecule114682133 yago:MonoclonalAntibody115029781 yago:OrganicCompound114727670 yago:Part113809207 yago:PhysicalEntity100001930 yago:Protein114728724 yago:Relation100031921 dbo:Drug yago:Substance100019613 yago:Thing100002452 yago:Unit109465459 |
| rdfs:comment |
Tralokinumab ist ein monoklonaler Antikörper, der zur Behandlung der atopischen Dermatitis (AD) angewendet wird. Im Juni 2021 wurde er unter dem Namen Adtralza (LEO Pharma) für die Länder der europäischen Union als Arzneimittel zugelassen. In Studien zur Behandlung von schwerem Asthma zeigte sich der Antikörper nicht ausreichend wirksam. (de) Tralokinumab sold under the brand names Adtralza (EU/UK) and Adbry (US) among others, is a human monoclonal antibody used for the treatment of atopic dermatitis. Tralokinumab targets the cytokine interleukin 13. The most common side effects include upper respiratory tract infections (colds and other infections of the nose and throat), reactions at the injection site, and redness and discomfort in the eye. Tralokinumab was approved for medical use in the European Union and in the United Kingdom in June 2021. It was approved for medical use in the United States in December 2021. (en) Тралокинумаб — лекарственный препарат, моноклональное антитело для лечения атопического дерматита. Одобрен для применения: EU, США (2021). (ru) |
| rdfs:label |
Tralokinumab (de) Tralokinumab (en) Тралокинумаб (ru) |
| owl:sameAs |
freebase:Tralokinumab yago-res:Tralokinumab wikidata:Tralokinumab dbpedia-de:Tralokinumab dbpedia-ru:Tralokinumab https://global.dbpedia.org/id/4wtns |
| prov:wasDerivedFrom |
wikipedia-en:Tralokinumab?oldid=1120064501&ns=0 |
| foaf:depiction |
wiki-commons:Special:FilePath/Tralokinumab_5L6Y.png |
| foaf:isPrimaryTopicOf |
wikipedia-en:Tralokinumab |
| is dbo:wikiPageRedirects of |
dbr:Tralokinumab-ldrm dbr:Adbry dbr:Adtralza |
| is dbo:wikiPageWikiLink of |
dbr:Cambridge_Antibody_Technology dbr:MedImmune dbr:Tralokinumab-ldrm dbr:Idiopathic_pulmonary_fibrosis dbr:Goblet_cell dbr:Adbry dbr:Atopic_dermatitis dbr:ATC_code_D11 dbr:Adtralza dbr:List_of_therapeutic_monoclonal_antibodies dbr:List_of_drugs:_Tr–Tri dbr:Type_2_inflammation |
| is foaf:primaryTopic of |
wikipedia-en:Tralokinumab |
